Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23890495 | 0.91 | LMNA (0.56) | POLBKMT2AHTTLMNAALDH1A1 | |
| SCHEMBL15431715 | 0.91 | POLB (0.43) | POLBKMT2AHTTLMNAALDH1A1 | |
| SCHEMBL13450100 | 0.91 | POLB (0.43) | POLBKMT2AHTTLMNAALDH1A1 | |
| SCHEMBL15199104 | 0.91 | POLB (0.43) | POLBKMT2AHTTLMNAALDH1A1 | |
| SCHEMBL18213834 | 0.91 | POLB (0.43) | POLBKMT2AHTTLMNAALDH1A1 | |
| SCHEMBL12057437 | 0.90 | SMN1; SMN2 (0.50) | POLBKMT2AHTTLMNAALDH1A1 | |
| SCHEMBL2757927 | 0.90 | SMN1; SMN2 (0.55) | POLBKMT2AHTTLMNAALDH1A1 | |
| SCHEMBL3213608 | 0.89 | POLB (0.42) | POLBKMT2AHTTLMNAALDH1A1 | |
| SCHEMBL3213595 | 0.89 | POLB (0.42) | POLBKMT2AHTTLMNAALDH1A1 | |
| SCHEMBL14296210 | 0.89 | GLA (0.53) | POLBKMT2AHTTLMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 119 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4645678-A | FOR FOOD OR PHARMACEUTICAL PRODUCTS | UNIVERSITE CLAUDE BERNARD - LYON 1 (FR) | 1987-02-24 | — | — | US | claimed |
| EP-0107597-B1 | CHEMICAL COMPOUNDS AND THEIR USE AS SWEETENING AGENTS | UNIVERSITE CLAUDE BERNARD - LYON 1 (FR) | 1986-02-26 | — | — | EP | claimed |
| EP-0107597-A1 | Chemical compounds and their use as sweetening agents | UNIVERSITE CLAUDE BERNARD - LYON 1 (FR) | 1984-05-02 | — | — | EP | claimed |
| US-20240390340-A1 | PYRROLIDINE KRAS INHIBITORS | INCYTE CORP (US) | 2024-11-28 | — | — | US | disclosed |
| US-11787779-B2 | Sulfone pyridine alkyl amide-substituted heteroaryl compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-10-17 | — | — | US | disclosed |
| US-11787779-B2 | Sulfone pyridine alkyl amide-substituted heteroaryl compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-10-17 | — | — | US | disclosed |
| US-20230286983-A1 | PYRIDINE-1,5-DIONES EXHIBITING MNK INHIBITION AND THEIR METHOD OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-09-14 | — | — | US | disclosed |
| US-20230286983-A1 | PYRIDINE-1,5-DIONES EXHIBITING MNK INHIBITION AND THEIR METHOD OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-09-14 | — | — | US | disclosed |
| US-20230278958-A1 | TRICYCLIC HETEROCYCLES | MERCK PATENT GMBH (DE) | 2023-09-07 | — | — | US | disclosed |
| US-20230278958-A1 | TRICYCLIC HETEROCYCLES | MERCK PATENT GMBH (DE) | 2023-09-07 | — | — | US | disclosed |
| US-20230265075-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | AJAX THERAPEUTICS, INC. | 2023-08-24 | — | — | US | disclosed |
| US-7557110-B2 | MAPKAP-K2; inflammatory disease, autoimmune disease, destructive bone disorder, cancer and/or tumour growth; 5-[(trans-4-aminocyclohexyl)amino]-3-fluoro-6-methyl(pyrazolo[1,5-a]pyri- midin-7-yl)}(4-iodophenyl)amine | TEIJIN PHARMA LIMITED (JP) | 2009-07-07 | — | — | US | disclosed |
| US-7557110-B2 | MAPKAP-K2; inflammatory disease, autoimmune disease, destructive bone disorder, cancer and/or tumour growth; 5-[(trans-4-aminocyclohexyl)amino]-3-fluoro-6-methyl(pyrazolo[1,5-a]pyri- midin-7-yl)}(4-iodophenyl)amine | TEIJIN PHARMA LIMITED (JP) | 2009-07-07 | — | — | US | disclosed |
| US-20090156553-A1 | PIPERAZINE COMPOUNDS WITH A HERBICIDAL ACTION | BASF SE (DE) | 2009-06-18 | — | — | US | disclosed |
| US-7504391-B2 | Selective D1/D5 receptor antagonists for the treatment of obesity and CNS disorders | SCHERING CORPORATION (US) | 2009-03-17 | — | — | US | disclosed |
| US-20070213315-A1 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED | 2007-09-13 | — | — | US | disclosed |
| US-20070197628-A1 | Cannabinoid receptor modulators | INTERVET INTERNATIONAL B.V. (NL) | 2007-08-23 | — | — | US | disclosed |
| US-20070149556-A1 | Hydroxypyrimidinone derivatives having inhibitory activity against hiv integrase | SHIONOGI & CO., LTD. (JP) | 2007-06-28 | — | — | US | disclosed |
| US-4645678-A | FOR FOOD OR PHARMACEUTICAL PRODUCTS | UNIVERSITE CLAUDE BERNARD - LYON 1 (FR) | 1987-02-24 | — | — | US | disclosed |
| EP-0107597-A1 | Chemical compounds and their use as sweetening agents | UNIVERSITE CLAUDE BERNARD - LYON 1 (FR) | 1984-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149556-A1 | Hydroxypyrimidinone derivatives having inhibitory activity against hiv integrase | HAT1, SULT1A1, CDK20 | POLB 143/4885KMT2A 1167/4885HTT 3291/4885 |
| US-20090156553-A1 | PIPERAZINE COMPOUNDS WITH A HERBICIDAL ACTION | DDT, CAT, CIP2A | POLB 3185/4885KMT2A 1094/4885HTT 580/4885 |
| US-20070213315-A1 | Modulators of muscarinic receptors | CHRM3, CHRM5, CHRM2 | POLB 4473/4885KMT2A 2362/4885HTT 3195/4885 |
| US-20230278958-A1 | TRICYCLIC HETEROCYCLES | YAP1, TERF2IP, TEAD1 | POLB 1569/4885KMT2A 2683/4885HTT 2473/4885 |
| US-11787779-B2 | Sulfone pyridine alkyl amide-substituted heteroaryl compounds | TYK2, JAK3, JAK2 | POLB 3486/4885KMT2A 1460/4885HTT 3425/4885 |
| US-20230265075-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | JAK2, JAK3, STAT5B | POLB 1228/4885KMT2A 462/4885HTT 1969/4885 |
| US-20240390340-A1 | PYRROLIDINE KRAS INHIBITORS | KRAS, NRAS, HRAS | POLB 68/4885KMT2A 3044/4885HTT 2358/4885 |
| US-20230286983-A1 | PYRIDINE-1,5-DIONES EXHIBITING MNK INHIBITION AND THEIR METHOD OF USE | DMPK, PDXK, NIM1K | POLB 801/4885KMT2A 1051/4885HTT 4637/4885 |
| US-20070197628-A1 | Cannabinoid receptor modulators | CNR1, CNR2, GPR18 | POLB 3689/4885KMT2A 1524/4885HTT 2641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.